• Minicabecera4

News

image354x212

Histocell , leader in Spain in cell therapy research and tissue engineering, will able to advance in clinical and industrial development of a new drug based on the use of lung cells for the treatment of idiopathic pulmonary fibrosis, a disease that causes irreversible and progressive loss of breathing capacity.

 



image354x212

It aims to promote the skills to be achieved by Master and PhD students.

As an extension of their vision of the relationship University - Company, the University of the Basque Country and Histocell, participate in an Innovative Education Research Project, which aims to promote the skills to be obtained by Master and PhD students, which includes not only methodological research aspects, but also integrating the development of priority skillsfor any business, such as teamwork, communication, planning and decision making, among others.

image354x212

Histocell, specializing in cell therapy applied to regenerative medicine and the pharmaceutical company Ferrer, have signed an agreement to develop a new cell therapy drug to treat spinal cord injuries of traumatic origin.